Larazotide Acetate — Safety, Research, Risks & Legal Status

Not medical advice. Larazotide Acetate is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	larazotide, Tight Junction Modulator, AT-1001
Category	Peptide
octapeptide	True
target_protein	MLCK, zonula occludens-1
indication_focus	Celiac disease
US legal status	Not FDA-approved; investigational drug candidate for celiac disease and other intestinal barrier disorders. In advanced clinical trials but not available for general purchase. Restricted to research and clinical trial settings.

What is Larazotide Acetate?

A synthetic octapeptide (8 amino acids) designed to modulate intestinal tight junction function. Increases barrier integrity by preventing unwanted paracellular transport and reducing zonula occludens-1 (ZO-1) disruption.

How it works

Larazotide binds myosin light-chain kinase (MLCK) and prevents ZO-1 phosphorylation. This stabilizes tight junction claudins and occludin, reducing paracellular leak.

Background & history

Developed by Cour Pharmaceuticals for celiac disease barrier dysfunction. Entered clinical trials around 2010; multiple Phase 3 trials conducted 2015-2020.

What the research says

Phase 3 clinical trials show larazotide reduces intestinal permeability in celiac disease patients and may reduce antibody responses to gluten. Human clinical trial data demonstrate modest efficacy for symptom reduction. Studies are ongoing; regulatory approval remains pending in most jurisdictions. Evidence is strongest for celiac-related conditions, with applicability to other barrier disorders under investigation.

Reported effects

Studied for intestinal tight junction restoration
Reported to reduce gluten-induced antibody responses in celiac disease
Researched for symptom reduction in celiac patients
Preliminary evidence for general intestinal barrier support
Clinical trial data exist, but approval status is ongoing

Dosing & administration (informational)

Clinical trials employed doses of 0.5 to 2 mg daily. Efficacy and tolerability appeared dose-dependent; optimal human regimen to be determined post-approval.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Still investigational; full safety profile not established in general populations
Well-tolerated in clinical trials; most adverse events mild (GI symptoms)
May interact with other medications or immune-modulating agents
Injectable; requires sterile administration with standard contamination precautions
Long-term safety data beyond trial durations not available

Drug & supplement interactions

May enhance effects of other barrier-supporting agents
Uncertain interaction with immunomodulatory drugs
Potential interaction with GI motility agents
No major drug-drug interactions documented in trials

Who should avoid it

Non-sterile or non-pharmaceutical-grade sources
Use without clinical oversight in autoimmune conditions
Concurrent high-dose immune-activating compounds
Administration to patients with severe GI inflammation or bleeding

How it is commonly combined

Larazotide combined with probiotics or other gut-supportive interventions is theoretical; clinical data absent.

Legal & regulatory. Not FDA-approved; investigational drug candidate for celiac disease and other intestinal barrier disorders. In advanced clinical trials but not available for general purchase. Restricted to research and clinical trial settings.

Quality & harm reduction

P
h
a
r
m
a
c
e
u
t
i
c
a
l
-
g
r
a
d
e
p
u
r
i
t
y
m
a
n
d
a
t
o
r
y
;
C
O
A
f
r
o
m
r
e
p
u
t
a
b
l
e
s
u
p
p
l
i
e
r
r
e
q
u
i
r
e
d
.
T
h
i
r
d
-
p
a
r
t
y
t
e
s
t
i
n
g
f
o
r
i
d
e
n
t
i
t
y
,
p
u
r
i
t
y
,
e
n
d
o
t
o
x
i
n
,
a
n
d
s
t
e
r
i
l
i
t
y
e
s
s
e
n
t
i
a
l
.

Lab testing & harm-reduction tools

If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.

Compare testing options

Frequently asked questions

Is larazotide approved by the FDA?

Not yet. Larazotide is in clinical trials for celiac disease and intestinal barrier disorders, but has not received FDA approval. It remains investigational.

How does larazotide work for celiac disease?

It modulates intestinal tight junctions to reduce intestinal permeability and prevent gluten peptides from triggering immune responses. It does not cure celiac disease but may reduce symptoms.

Can I buy larazotide outside of clinical trials?

Not legally in most jurisdictions. It is restricted to approved clinical trials and research settings. Some countries may have compassionate use programs.

What are the main side effects?

In clinical trials, the most common side effects are mild gastrointestinal symptoms. Serious adverse events have been rare, but long-term safety is still being characterized.

Is larazotide a cure for celiac disease?

No. Larazotide is not a cure; it is a symptomatic barrier-support agent. Gluten avoidance remains the primary celiac disease management strategy.

References & further reading

C
e
l
i
a
c
d
i
s
e
a
s
e
c
l
i
n
i
c
a
l
r
e
s
e
a
r
c
h
;
i
n
t
e
s
t
i
n
a
l
b
a
r
r
i
e
r
p
h
y
s
i
o
l
o
g
y
j
o
u
r
n
a
l
s
;
P
h
a
s
e
3
t
r
i
a
l
l
i
t
e
r
a
t
u
r
e
a
n
d
r
e
g
u
l
a
t
o
r
y
s
u
b
m
i
s
s
i
o
n
s
.